HVTN Laboratory Program: Immunogenicity and Research Assays

Size: px
Start display at page:

Download "HVTN Laboratory Program: Immunogenicity and Research Assays"

Transcription

1 HVTN Laboratory Program: Immunogenicity and Research Assays Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda March 2015

2 Overview Overview of the HVTN Laboratory Center Validated assay examples ICS BAMA Research assay examples Innate responses/systems biology Mucosal

3 HVTN Laboratory Center: Key Players NIAID Division of AIDS Clinical Vaccine Branch Cross Network HIV Activities HIV Vaccine Enterprise Non-HIV Vaccine Activities Scientific Leadership Julie McElrath, PI and Director Nicole Frahm, Associate Director, FHCRC Lab Science Georgia Tomaras, Associate Director, Duke Lab Science John Hural, Associate Director, LC Operations Key Investigators Stephen DeRosa, David Montefiori Erica Andersen-Nissen, Lynn Morris Lab Sciences Advisory Board HVTN Leadership and Operations Center HVTN Statistical and Data Management Center Cellular & Innate Studies Laboratory Center Operations Humoral Studies Fred Hutchinson Cancer Research Center Cape Town HVTN Laboratory Specialized Working Groups Virus & Host Genetics, Systems Biology, Mucosal Immunity, HIV Diagnostics, TB Immunology, NHP HIV Diagnostics Repositories QA/QC Site Affiliated Labs Protocol Support Labs Viral Genetics, Host Genetics, Anti-Vector Analysis Duke University NICD

4 Expansion of the HVTN Core Lab Network: South Africa Cellular Responses Humoral Responses Lynn Morris s Group NICD, Johannesburg CHIL, Cape Town Cape Town HVTN Immunology Laboratory (CHIL)

5 Validated Endpoints Assays Assays are critical for decisions to advance vaccine candidates Performed under GCLP conditions Formally validated using industry standard processes Enable cross-protocol comparisons between regimens Intracellular cytokine staining (ICS) Establishing concordance Analysis of HVTN 097 T cell responses Binding Antibodies Measuring breadth of binding Ab responses in HVTN 097

6 Intracellular Cytokine Staining (ICS) Assay RV144 Ab Staining Panel

7 ICS Assay Concordance: Seattle/Cape Town Background subtracted correlations of positive ICS responses (Percent T cells expressing IFN-γ and/or IL-2 after peptide stimulation) CMV ENV CD4 CD8 Cape Town Seattle Colors indicate data from different HVTN trials

8 Binding Antibody Multiplex Assay (BAMA) ~100 Antigens in a Single Sample Validated for Clinical Trials Small volume allows interrogation of mucosal samples Tomaras et al. (2008) J. Virol Haynes et al. (2012) NEJM Yates, Tomaras (2013) Nature Mucosal Immunology Eckels et al BMC Bioinformatics Yates, Tomaras (2014) Science Trans. Medicine Georgia Tomaras, Duke University

9 V1-V2 Breadth Immune Monitoring Assays New well-characterized cross-clade antigen panels to cover subtypes AE, A, B, BC, and C from diverse geographic regions (Malawi, China, Thailand, South Africa, US, India, Zambia, Uganda, Trinidad, Kenya). Envelope Panel: 8 gp120, and 8 gp140 gp70 V1-V2 Panel: 16 gp70 V1-V2 Yates, DeCamp, Alam, Pinter, Korber, Montefiori, Tomaras and BMGF et al. In Prep Georgia Tomaras, Duke University

10 Research Assays: Innate/Systems Biology How do innate responses to vaccination predict adaptive responses? Vaccina.on ICS Assay (T cell responses) Weeks: Innate.me points (hours): Whole blood (enumeration of cell populations) - Serum (cytokine concentrations) - Cells (gene expression profiling) Identify innate responses that predict adaptive responses Erica Andersen-Nissen

11 Change in expression of over 200 genes at 72 hrs post vaccination with MRKAD5 predicts CD8+ T cell ICS responses to HIV Gag at 4 weeks SH2D1B/EAT-2: expressed in APC; Increases cellular immune responses (Aldhamen et al., 2011) 11 3/25/15 11 Zak, Andersen-Nissen et al, PNAS 2012

12 Analysing the contribution of innate cells to the vaccine response -What can we learn about the role of different cell types in the innate response to HIV vaccines? -How will this help us to better target certain responses? Average Log2(Fold change) > 0.5 P<0.05 for at least 1 cell type n=7 Erica Andersen-Nissen

13 Research Assays: Mucosal Immunology HIV transmission in mucosal tissues Several antibody functions may contribute to HIV protection: Neutralization Blocking virus interaction with non-canonical receptors (e.g. DC-SIGN) Complement activation Phagocytosis Antibody-dependent, cellular cytotoxicity (ADCC) many depend on Fc receptors (FcRs) McElrath & Haynes, Immunity 2010 relative distribution of FcR-bearing effector cells in mucosa is not well defined. Rena Astronomo, FHCRC

14 Ex vivo mucosal challenge assay: Examine Ab inhibition of viral infection Trim tissue, cut into explants and wash with cold PBS Culture overnight w/ PHA, IL-2, -7 & -15 Add virus pre-incubated with Ab OR Ab and virus simultaneously Wash out virus 2-3 mm vaginal explants Culture up to 21 days collecting media or tissue for readout Rena Astronomo, FHCRC

15 Assay Development and Standardization: Control Cohorts are Invaluable! HIV positive and healthy HIV negative volunteers Scheduled visits as well as flexibility for additional asneeded visits Collect: Blood (whole blood, PBMC, plasma, serum) Leukapheresis Cervical/vaginal/rectal fluid Cytobrush, semen Cervical/vaginal biopsies Rectal/Sigmoid colon biopsies

16 Please Come Visit CHIL!

17 Acknowledgements HVTN Lab Center Julie McElrath Georgia Tomaras Nicole Frahm Steve DeRosa John Hural HVTN 097 Protocol Team Glenda Grey Nicole Grunenberg Ying Huang Niya Gu Volunteers Rena Astronomo Dan Zak Alan Aderem Linda- Gail Bekker Lyne\e Denny Carolyn Williamson Funders /DAIDS Patricia D Souza Mary Marovitch Carl Dieffenbach Siobhan Malone Glenda Gray Michelle Mulder

Higher priming doses enhance HIV-specific humoral but not cellular. responses in a randomized, double-blind phase Ib clinical trial of

Higher priming doses enhance HIV-specific humoral but not cellular. responses in a randomized, double-blind phase Ib clinical trial of Higher priming doses enhance HIV-specific humoral but not cellular responses in a randomized, double-blind phase Ib clinical trial of preventive HIV-1 vaccines Pierre-Alexandre Bart a,b, Yunda Huang c,

More information

HVTN P5 Vaccine Trials

HVTN P5 Vaccine Trials HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission

More information

Why are validated immunogenicity assays important for HIV vaccine development?

Why are validated immunogenicity assays important for HIV vaccine development? Why are validated immunogenicity assays important for HIV vaccine development? There is a need to compare immunogenicity of products in the pipeline, when similar or different in class when developed by

More information

Application of systems biology to identify predictors of HIV vaccine immunogenicity

Application of systems biology to identify predictors of HIV vaccine immunogenicity Application of systems biology to identify predictors of HIV vaccine immunogenicity Daniel Zak 1, Erica Andersen-Nissen 2, Haesun Park 3, Scott Hansen 3, Karl Mullen 3, Kristi Hamilton 1, Kathleen Kennedy

More information

The Kitchen Sink. Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona

The Kitchen Sink. Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona The Kitchen Sink Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona The only important slide of my presentation. All efficacy trial in

More information

Induction of Innate Immune Responses in HVTN 071: a Trial using the MRKAd5 gag/pol/nef Vaccine from the Step Study

Induction of Innate Immune Responses in HVTN 071: a Trial using the MRKAd5 gag/pol/nef Vaccine from the Step Study Induction of Innate Immune Responses in HVTN 71: a Trial using the MRKAd5 gag/pol/nef Vaccine from the Step Study Erica Andersen-Nissen Vaccine and Infectious Disease Institute Fred Hutchinson Cancer Research

More information

Virus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies

Virus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies Virus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies Michael Seaman, Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Harvard Medical School J. Virol.

More information

Increasing Neutralisation resistance in HIV-1 Clade C over the course of the southern African Epidemic. Cecilia Rademeyer 26 October 2014

Increasing Neutralisation resistance in HIV-1 Clade C over the course of the southern African Epidemic. Cecilia Rademeyer 26 October 2014 Increasing Neutralisation resistance in HIV-1 Clade C over the course of the southern African Epidemic. Cecilia Rademeyer 26 October 2014 HIV-1 Transmission and Antigenic Drift Individual Selection Transmission

More information

HIV: RV 144 prime boost HIV vaccine efficacy study

HIV: RV 144 prime boost HIV vaccine efficacy study HIV: RV 144 prime boost HIV vaccine efficacy study Nelson L. Michael, M.D., Ph.D Colonel, Medical Corps, U.S. Army Director US Military HIV Research Program (MHRP) Walter Reed Army Institute of Research

More information

Evaluation of lead HIV-1 vaccine regimen in APPROACH:

Evaluation of lead HIV-1 vaccine regimen in APPROACH: Evaluation of lead HIV-1 vaccine regimen in : Phase 1/2a study testing heterologous prime boost regimens using mosaic Ad26 and MVA vectors combined with Env protein Hanneke Schuitemaker Martin Freeman,

More information

Antibody Dependent Cellular Cytotxic activity: Past and Future. Guido Ferrari, M.D. Duke University Medical Center

Antibody Dependent Cellular Cytotxic activity: Past and Future. Guido Ferrari, M.D. Duke University Medical Center Antibody Dependent Cellular Cytotxic activity: Past and Future Guido Ferrari, M.D. Duke University Medical Center Mechanism of Antibody Dependent Cellular Cytotoxicity (ADCC) ADCC Effector Cells (NK, monocytes/macrophages,

More information

Immunogenicity of ALVAC HIV (vcp1521) and AIDSVAX B/E Prime Boost Vaccination in RV144, Thai Phase III HIV Vaccine Trial

Immunogenicity of ALVAC HIV (vcp1521) and AIDSVAX B/E Prime Boost Vaccination in RV144, Thai Phase III HIV Vaccine Trial Immunogenicity of ALVAC HIV (vcp1521) and AIDSVAX B/E Prime Boost Vaccination in RV144, Thai Phase III HIV Vaccine Trial M. de Souza, R. Trichavaroj, A. Schuetz, W. Chuenarom, Y. Phuang ngern, S. Jongrakthaitae,

More information

Planned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP

Planned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP Planned Vaccine Trials to Follow-up on RV 144 Merlin Robb, MD Deputy Director for Clinical Research MHRP Planned studies are mutually reinforcing and will amplify public health impact and regional relevance

More information

HVTN RAMP Mentors

HVTN RAMP Mentors 2016-2017 RAMP Scholars travel to an HVTN site and work closely with a mentor to conduct an HIV vaccine research project. We recommend that interested students e-mail Jenna Udren, RAMP Project Coordinator

More information

Lynn Morris. "Plan B"- bnabs for HIV prevention

Lynn Morris. Plan B- bnabs for HIV prevention "Plan B"- bnabs for HIV prevention Lynn Morris National Institute for Communicable Diseases, a division of the National Health Laboratory Service (NHLS) of South Africa, University of the Witwatersrand,

More information

Professor Andrew McMichael

Professor Andrew McMichael BHIVA AUTUMN CONFERENCE 2011 Including CHIVA Parallel Sessions Professor Andrew McMichael University of Oxford 17 18 November 2011, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE

More information

Innate and Cellular Immunology Control of Infection by Cell-mediated Immunity

Innate and Cellular Immunology Control of Infection by Cell-mediated Immunity Innate & adaptive Immunity Innate and Cellular Immunology Control of Infection by Cell-mediated Immunity Helen Horton PhD Seattle Biomedical Research Institute Depts of Global Health & Medicine, UW Cellular

More information

Challenges of Integrating Mucosal Immune Assays into HIV Vaccine Trials KAVI

Challenges of Integrating Mucosal Immune Assays into HIV Vaccine Trials KAVI Challenges of Integrating Mucosal Immune Assays into HIV Vaccine Trials Omu Anzala, MBChB, PhD KAVI University of Nairobi Outline Why mucosal immunology Experience from Kenya Challenges The way forward

More information

EDCTP Third Forum PARTNERSHIP AND AFRICAN LEADERSHIP IN VACCINE RESEARCH AND HIV/AIDS DRUG. MBOUP Souleymane

EDCTP Third Forum PARTNERSHIP AND AFRICAN LEADERSHIP IN VACCINE RESEARCH AND HIV/AIDS DRUG. MBOUP Souleymane EDCTP Third Forum PARTNERSHIP AND AFRICAN LEADERSHIP IN VACCINE RESEARCH AND HIV/AIDS DRUG MBOUP Souleymane HIV VACCINE IN AFRICA In 2005, 13 new trials of preventive AIDS vaccine candidates began in 9

More information

EMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV. (Summary of the recommendations from an Enterprise Working Group)

EMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV. (Summary of the recommendations from an Enterprise Working Group) AIDS Vaccine 07, Seattle, August 20-23, 2007 EMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV (Summary of the recommendations from an Enterprise Working Group) The Working Group Reston, Virginia,

More information

SAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL

SAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL SAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL Glenda Gray President & CEO SAMRC 1 SA AIDS 2017 Durban 15 June 2017 Partner logo LEADERSHIP IN A TIME OF UNCERTAINTY 2 BASELINE BUDGET

More information

HIV and Challenges of Vaccine Development

HIV and Challenges of Vaccine Development Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST

More information

Current State of HIV Vaccine Development

Current State of HIV Vaccine Development Current State of HIV Vaccine Development Sandhya Vasan, MD US Military HIV Research Program Henry M. Jackson Foundation Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand AVAC HVAD

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Barouch DH, Tomaka FL Wegmann F, et al. Evaluation

More information

Trials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference April, 2016

Trials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference April, 2016 Trials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference 2016 13-16 April, 2016 Scope Rationale for an HIV vaccine RV144 study in Thailand

More information

NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections

NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections Amy Chung Dr. Ivan Stratov Prof. Stephen Kent ADCC process consists of Target cell QuickTime and a TIFF (Uncompressed) FcγR decompressor

More information

Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants

Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants Office of AIDS Research Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants L. Jean Patterson, PhD Office of AIDS Research, NIH February 7, 2017 Office of AIDS Research OAR Responsibilities

More information

FUNDERS UPDATE- BMGF. Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017

FUNDERS UPDATE- BMGF. Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017 FUNDERS UPDATE- BMGF Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017 Susan Barnett Senior Program Officer, Product and Clinical

More information

HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial

HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial The Journal of Clinical Investigation Clinical Medicine HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial Pierre-Alexandre Bart, 1,2,11 Yunda Huang, 3,11 Shelly T. Karuna,

More information

GOVX-B11: A Clade B HIV Vaccine for the Developed World

GOVX-B11: A Clade B HIV Vaccine for the Developed World GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in

More information

Should There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies?

Should There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies? Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Should There be Further Efficacy

More information

Are we targeting the right HIV determinants?

Are we targeting the right HIV determinants? QuickTime et un décompresseur TIFF (non compressé) sont requis pour visionner cette image. AIDS Vaccine 2009 October 22 nd 2009 - Paris Are we targeting the right HIV determinants? Françoise BARRÉ-SINOUSSI

More information

Tricks in HIV s bag to counter vaginal or rectal microbicides

Tricks in HIV s bag to counter vaginal or rectal microbicides Tricks in HIV s bag to counter vaginal or rectal microbicides Florian Hladik, MD, PhD University of Washington Fred Hutchinson Cancer Research Center Seattle Contribution of the various HIV invasion routes

More information

Efficacy Results from the Step Study

Efficacy Results from the Step Study Efficacy Results from the Step Study (Merck V520 Protocol 023/HVTN 502) A Phase II Test-of-Concept Trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent Vaccine CROI February 5, 2008 Boston, MA Rationale for

More information

Novel Heterologous Prime-Boost Vaccine Strategies for HIV. Dan Barouch April 18, 2012

Novel Heterologous Prime-Boost Vaccine Strategies for HIV. Dan Barouch April 18, 2012 Novel Heterologous Prime-Boost Vaccine Strategies for HIV Dan Barouch April 18, 2012 Desired Features of a Next Generation HIV-1 Vaccine Candidate The RV1 study suggests that an HIV-1 vaccine is possible

More information

Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH. Division of Infectious Diseases Columbia University Medical Center

Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH. Division of Infectious Diseases Columbia University Medical Center Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH Division of Infectious Diseases Columbia University Medical Center 1 Outline A short history of HIV vaccine design and development Describe

More information

REIGNITING RECRUITMENT

REIGNITING RECRUITMENT a Publication of the HIV Vaccine Trials Network Volume 4, issue 1 july, 2012 REIGNITING RECRUITMENT IN THIS ISSUE 02 03 06 07 10 13 ARTICLES Probing the Diversity of Vaccine Elicited HIV-1 Antibodies:

More information

Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study

Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a

More information

Cent Gardes Conference: HIV Vaccines. Organized by Fondation Mérieux «Les Pensières» Fondation Mérieux Conference Center Veyrier du Lac - France

Cent Gardes Conference: HIV Vaccines. Organized by Fondation Mérieux «Les Pensières» Fondation Mérieux Conference Center Veyrier du Lac - France Cent Gardes Conference: HIV Vaccines Organized by Fondation Mérieux «Les Pensières» Fondation Mérieux Conference Center Veyrier du Lac - October 6 to 8, 2017 Steering Committee Members Françoise Barré-Sinoussi

More information

Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood

Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood tree illustrating CRF01_AE gp120 protein sequence relationships between 107 Envs sampled in the RV144 trial

More information

TB vaccine progress. Hassan Mahomed. Institute of Infectious Disease and Molecular Medicine, School of Child and Adolescent Health,

TB vaccine progress. Hassan Mahomed. Institute of Infectious Disease and Molecular Medicine, School of Child and Adolescent Health, TB vaccine progress Hassan Mahomed South African TB Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine, School of Child and Adolescent Health, University of Cape Town, South

More information

HIV Vaccine Clinical Trials at CIDRZ

HIV Vaccine Clinical Trials at CIDRZ HIV Vaccine Clinical Trials at CIDRZ Developing a Safe and Effective Vaccine for Prevention of HIV Infections Globally Christine Namakobo Senior Research Nurse Matero Clinical Research Site State of Global

More information

MTN-020 and IPM 027 and the MTN-020 DSMB. Jared Baeten, MD PhD Thesla Palanee, PhD ASPIRE Protocol Team Meeting 22 February 2012

MTN-020 and IPM 027 and the MTN-020 DSMB. Jared Baeten, MD PhD Thesla Palanee, PhD ASPIRE Protocol Team Meeting 22 February 2012 MTN-020 and IPM 027 and the MTN-020 DSMB Jared Baeten, MD PhD Thesla Palanee, PhD ASPIRE Protocol Team Meeting 22 February 2012 Developing a range of options for antiretroviral-based HIV prevention Pill

More information

Cent Gardes Conference: HIV Vaccines. Organized by Fondation Mérieux Les Pensières Center for Global Health Veyrier du Lac - France

Cent Gardes Conference: HIV Vaccines. Organized by Fondation Mérieux Les Pensières Center for Global Health Veyrier du Lac - France Cent Gardes Conference: HIV Vaccines Organized by Fondation Mérieux Les Pensières Center for Global Health Veyrier du Lac - October 6th to 8th, 2017 Steering Committee Members Françoise Barré-Sinoussi

More information

HIV cure: current status and implications for the future

HIV cure: current status and implications for the future HIV cure: current status and implications for the future Carolyn Williamson, PhD Head of Medical Virology, Faculty Health Sciences, University of Cape Town CAPRISA Research Associate, Centre of Excellence

More information

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case cohort analysis

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case cohort analysis HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case cohort analysis M Juliana McElrath, Stephen C De Rosa, Zoe Moodie, Sheri Dubey, Lisa Kierstead, Holly Janes, Olivier D Defawe, Donald

More information

Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates

Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates Vaccines 2014, 2, 15-35; doi:10.3390/vaccines2010015 Review OPEN ACCESS vaccines ISSN 2076-393X www.mdpi.com/journal/vaccines Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune

More information

staining and flow cytometry

staining and flow cytometry Detection of influenza virus-specific T cell responses by intracellular by cytokine intracellular staining cytokine staining and flow cytometry Detection of influenza virus-specific T cell responses and

More information

Ad35.CS.01 RTS,S/AS01 prime boost second generation malaria vaccine candidate

Ad35.CS.01 RTS,S/AS01 prime boost second generation malaria vaccine candidate Ad35.CS.01 /AS01 prime boost second generation malaria vaccine candidate Johan Vekemans MD, PhD Malaria vaccines Global Vaccine Development GSK Biologicals NIH 2012 1 The need for a malaria vaccine: targets

More information

Third Env Manufacturing Workshop July 20 21, July 20, 2017 Mary Marovich, M.D. Director, Vaccine Research Program

Third Env Manufacturing Workshop July 20 21, July 20, 2017 Mary Marovich, M.D. Director, Vaccine Research Program Third Env Manufacturing Workshop July 20 21, 2017 July 20, 2017 Mary Marovich, M.D. Director, Vaccine Research Program Presentation Outline Importance and Impact of an HIV Vaccine DAIDS/VRP Programmatic

More information

A Quarterly Update on HIV Prevention Research. Vol. 8 No. 2

A Quarterly Update on HIV Prevention Research. Vol. 8 No. 2 What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered

More information

CD4 + T-cell-inducing HIV vaccines may have an impact on viral control

CD4 + T-cell-inducing HIV vaccines may have an impact on viral control CD4 + T-cell-inducing HIV vaccines may have an impact on viral control Clues from cytokines produced by CD4 + T-cells from HIVinfected patients and vaccinated seronegative volunteers Eva Van Braeckel 1,

More information

Phase 1 Human Trials of Rectal Microbicides

Phase 1 Human Trials of Rectal Microbicides Phase 1 Human Trials of Rectal Microbicides UC781: Completed Tenofovir: Planned to start an NIH IPCP for Topical Microbicides RM Trials under U19-IPCP grant UC781 (topical) rectal trial completed A Phase

More information

Partners in Prevention Lessons Learned Importance of Network Culture & Feedback Relevance for MTN

Partners in Prevention Lessons Learned Importance of Network Culture & Feedback Relevance for MTN Partners in Prevention Lessons Learned Importance of Network Culture & Feedback Relevance for MTN MTN Annual Regional Meeting, Cape Town September 2008 Connie Celum, MD, MPH Clinical trials require. Important,

More information

Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers

Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers Adam R. Hersperger Department of Microbiology University of Pennsylvania Evidence for

More information

HVTN HIV Diagnostics Program

HVTN HIV Diagnostics Program HVTN HIV Diagnostics Program John Hural, Ph.D. Carissa Karg, MPH March 14, 2013 The HVTN is supported through a cooperative agreement with the National Institute of Allergy and Infectious Diseases 1 HIV

More information

May HIV Vaccines: The Basics

May HIV Vaccines: The Basics May 2018 HIV Vaccines: The Basics Presentation Overview What is a vaccine? How would an HIV vaccine work? Where are we in the search? What is needed now? What is a Vaccine? A substance that teaches the

More information

Sommer. Memorial. Lectures

Sommer. Memorial. Lectures Getting to an HIV Vaccine: Necessity and Frustration Larry Corey, MD Principal Investigator, NIAID supported HIV Vaccine Trials Network (HVTN) Past President and Director, Fred Hutchinson Cancer Research

More information

Advancing HIV Vaccines into Efficacy studies. Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland

Advancing HIV Vaccines into Efficacy studies. Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland Advancing HIV Vaccines into Efficacy studies Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland What we need to end AIDS: controlling viremia New classes of Drugs Point of care viral load &

More information

AGE DA. 8:00-8:30 Breakfast All. 8:30-8:40 Introductions All. 8:40-8:55 Mandate of the Enterprise Alan Bernstein

AGE DA. 8:00-8:30 Breakfast All. 8:30-8:40 Introductions All. 8:40-8:55 Mandate of the Enterprise Alan Bernstein 200 Park Ave. S. Suite 1501 New York, NY 10003 Ph: +1 866 966 4483 +1 212 461 3692 Fax: +1 212 780 0607 THE GLOBAL HIV VACCI E E TERPRISE (THE E TERPRISE) I AUGURAL MEETI G OF THE SCIE CE COMMITTEE WED

More information

HIV-1 acute infection: evidence for selection?

HIV-1 acute infection: evidence for selection? HIV-1 acute infection: evidence for selection? ROLLAND Morgane University of Washington Cohort & data S6 S5 T4 S4 T2 S2 T1 S1 S7 T3 DPS (days post symptoms) 3 (Fiebig I) 7 (Fiebig I) 13 (Fiebig V) 14 (Fiebig

More information

Module 8: Evaluating Immune Correlates of Protection

Module 8: Evaluating Immune Correlates of Protection Module 8: Evaluating Immune Correlates of Protection Instructors: Ivan Chan, Peter Gilbert, Paul T. Edlefsen, Ying Huang Session 7: RV144 Thai Trial Case Study (HIV Vaccine Efficacy Trial) Summer Institute

More information

HIV/AIDS: vaccines and alternate strategies for treatment and prevention

HIV/AIDS: vaccines and alternate strategies for treatment and prevention Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Online Meeting Report HIV/AIDS: vaccines and alternate strategies for treatment and prevention Yegor Voronin 1 and Sanjay

More information

HIV Vaccine. 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง

HIV Vaccine. 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง HIV Vaccine 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง GLOBAL STATISTICS 2015 17 million people were accessing antiretroviral therapy 36.7 million people globally

More information

محاضرة مناعت مدرس المادة :ا.م. هدى عبدالهادي علي النصراوي Immunity to Infectious Diseases

محاضرة مناعت مدرس المادة :ا.م. هدى عبدالهادي علي النصراوي Immunity to Infectious Diseases محاضرة مناعت مدرس المادة :ا.م. هدى عبدالهادي علي النصراوي Immunity to Infectious Diseases Immunity to infection depends on a combination of innate mechanisms (phagocytosis, complement, etc.) and antigen

More information

ALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen. Results of the Thai HIV Vaccine Trial, RV144

ALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen. Results of the Thai HIV Vaccine Trial, RV144 ALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen Results of the Thai HIV Vaccine Trial, RV144 SupachaiRerks-Ngarm, PunneePittisutthithum, SorachaiNitayaphan, JaranitKaewkungwal,

More information

Preparations for HIV Vaccine Research at Zambia-Emory HIV Research Project (ZEHRP)

Preparations for HIV Vaccine Research at Zambia-Emory HIV Research Project (ZEHRP) Preparations for HIV Vaccine Research at Zambia-Emory HIV Research Project (ZEHRP) William Kilembe 1, Susan Allen 1,2, Elwyn Chomba 3, Cheswa Vwalika 1, Shabir Lakhi 1,3, Olivier Manigart 1, Patricia Fast

More information

Developing TB Vaccine Clinical Trial Capacity Aeras Perspective. Vicky Cardenas, PhD, JD

Developing TB Vaccine Clinical Trial Capacity Aeras Perspective. Vicky Cardenas, PhD, JD Developing TB Vaccine Clinical Trial Capacity Aeras Perspective Vicky Cardenas, PhD, JD ASEAN-EU STI Days 21-23 January 2014 Aeras Founded in 2003 Mission: Develop improved TB vaccines that are affordable

More information

Cellular Immunity in Aging and HIV: Correlates of Protection. Immune Senescence

Cellular Immunity in Aging and HIV: Correlates of Protection. Immune Senescence Cellular Immunity in Aging and HIV: Correlates of Protection Janet E. McElhaney, MD Professor of Medicine Allan M. McGavin Chair in Research Geriatrics University of British Columbia Vancouver, BC and

More information

Induction and Clearance of Latent HIV Infection:

Induction and Clearance of Latent HIV Infection: 214 Towards an HIV Cure symposium Melbourne Induction and Clearance of Latent HIV Infection: an Ex-Vivo Assessment of Immune Effectors using Cells from ART-treated Patients DM Margolis 1, C Garrido 1,

More information

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve

More information

Combinatorial Vaccines for AIDS and other Infectious Diseases

Combinatorial Vaccines for AIDS and other Infectious Diseases Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Combinatorial Vaccines for AIDS

More information

Start Date* Sites Description

Start Date* Sites Description HVTN 076 17 HVTN HVTN 084 100 HVTN HVTN 085 90 HVTN HVTN 096 96 HVTN IPPOX EuroVacc GSID USMHRP HVTN 098 94 HVTN Inovio clade B AIDSVAX B/E clade C NYVAC clade C PENNVAX-GP IL-12 adjuvant September-11

More information

Professor Jonathan Weber

Professor Jonathan Weber THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Jonathan Weber Imperial College, London 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor

More information

4/14/2016. HIV Vaccines and Immunoprotection: Where Are We? Learning Objectives. After attending this presentation, participants will be able to:

4/14/2016. HIV Vaccines and Immunoprotection: Where Are We? Learning Objectives. After attending this presentation, participants will be able to: HIV Vaccines and Immunoprotection: Where Are We? Mark J. Mulligan, MD, FIDSA Distinguished Professor of Medicine Emory University School of Medicine Atlanta, Georgia FINAL: 04/01/16 Atlanta, Georgia: Friday,

More information

Heterosubtypic immunity. Professor Ajit Lalvani FMedSci Chair of Infectious Diseases 14/07/2014

Heterosubtypic immunity. Professor Ajit Lalvani FMedSci Chair of Infectious Diseases 14/07/2014 Protective cellular immune correlates against pandemic influenza: implications for universal vaccines 2 nd WHO Meeting on development and clinical trials of broadly protective influenza vaccines 5th 7th

More information

HIV Vaccines: Basic Science

HIV Vaccines: Basic Science Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV Vaccines: Basic Science Richard A. Koup, MD 6 th INTEREST Workshop

More information

In pursuit of an HIV vaccine: an interview with Andrew McMichael

In pursuit of an HIV vaccine: an interview with Andrew McMichael McMichael BMC Biology 2013, 11:60 INTERVIEW Open Access In pursuit of an HIV vaccine: an interview with Andrew McMichael Andrew J McMichael Andrew McMichael qualified in Medicine before doing a PhD in

More information

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.

More information

Correlates of Immunity: RV144 - Lessons Learned

Correlates of Immunity: RV144 - Lessons Learned Correlates of Immunity: RV144 - Lessons Learned US Military HIV Research Program (MHRP) Nelson L. Michael, MD, PhD AIDS Vaccine 2010, Atlanta GA 01 October 2010 Outline RV 144 Correlates Discovery Towards

More information

Where We Have Been and Where We are Going. Ian McGowan MD PhD FRCP

Where We Have Been and Where We are Going. Ian McGowan MD PhD FRCP Where We Have Been and Where We are Going Ian McGowan MD PhD FRCP Directions Where we were Where we are headed Where we are 2005 The size of your dreams must always exceed your current capacity to achieve

More information

Summer!2016! Undergraduate! Research! Internships!

Summer!2016! Undergraduate! Research! Internships! Summer2016 Undergraduate Research Internships Qualifications:- 1.18yearsofageorolder. 2.MustattendPLU,SeattleU,SPUorbealocalundergraduatemilitaryveteran. 3.EnteringjuniororpreferablysenioryearinFall2016.

More information

Adaptive Immunity: Specific Defenses of the Host

Adaptive Immunity: Specific Defenses of the Host 17 Adaptive Immunity: Specific Defenses of the Host SLOs Differentiate between innate and adaptive immunity, and humoral and cellular immunity. Define antigen, epitope, and hapten. Explain the function

More information

Regional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South Africa

Regional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South Africa JOURNAL OF VIROLOGY, Mar. 2002, p. 2233 2244 Vol. 76, No. 5 0022-538X/02/$04.00 0 DOI: 10.1128/JVI.76.5.2233 2244.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. Regional Clustering

More information

Perspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis

Perspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis Perspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis Existing TB Vaccine is not effective for global TB epidemic control BCG

More information

Module 8: Introduction to Immune Correlates of Protection. Instructors: Ivan Chan, Peter Gilbert, Paul T. Edlefsen, Ying Huang

Module 8: Introduction to Immune Correlates of Protection. Instructors: Ivan Chan, Peter Gilbert, Paul T. Edlefsen, Ying Huang Module 8: Evaluating Immune Correlates of Protection Instructors: Ivan Chan, Peter Gilbert, Paul T. Edlefsen, Ying Huang Session 7: RV144 Thai Trial Case Study (HIV Vaccine Efficacy Trial) Summer Institute

More information

Fostering Clinical Development for HIV-1 Vaccine

Fostering Clinical Development for HIV-1 Vaccine W Fostering Clinical Development for HIV-1 Vaccine Ravimiarenduse alane seminar 9. oktoobril Tallinnas Mart Ustav, PhD CSO, SVP 1 FIT Biotech Founded in 1995 Operations in Tampere, Finland and Tartu, Estonia

More information

Chronic HIV-1 Infection Frequently Fails to Protect against Superinfection

Chronic HIV-1 Infection Frequently Fails to Protect against Superinfection Chronic HIV-1 Infection Frequently Fails to Protect against Superinfection Anne Piantadosi 1,2[, Bhavna Chohan 1,2[, Vrasha Chohan 3, R. Scott McClelland 3,4,5, Julie Overbaugh 1,2* 1 Division of Human

More information

HIV vaccine research and development

HIV vaccine research and development HIV vaccine research and development What is an HIV vaccine and how does it work? An HIV vaccine is a substance given to the body to teach it to defend itself against HIV. A successful preventative HIV

More information

The challenge of an HIV vaccine from the antibody perspective. Dennis Burton The Scripps Research Institute

The challenge of an HIV vaccine from the antibody perspective. Dennis Burton The Scripps Research Institute The challenge of an HIV vaccine from the antibody perspective Dennis Burton The Scripps Research Institute AIDS Pandemic Nov 2005 North America 1.2 million [650 000 1.8 million] Caribbean 300 000 [200

More information

South African Guidelines for the Safe Use of. Dr. Oscar Radebe

South African Guidelines for the Safe Use of. Dr. Oscar Radebe South African Guidelines for the Safe Use of PrEP in MSM Dr. Oscar Radebe Background Globally MSM(men who have sex with men) have been disproportionately at high risk of HIV transmission. Biological &

More information

Long-acting Antivirals Where Are We Headed? Are We Ready? Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID May 3, 2018

Long-acting Antivirals Where Are We Headed? Are We Ready? Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID May 3, 2018 Long-acting Antivirals Where Are We Headed? Are We Ready? Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID May 3, 2018 Global HIV Statistics 2017 People living with HIV in 2016 New HIV infections

More information

CBER update and International Collaboration for development of HIV variant panels

CBER update and International Collaboration for development of HIV variant panels CBER update and International Collaboration for development of HIV variant panels Indira K. Hewlett, Ph.D Chief, Laboratory of Molecular Virology DETTD/CBER/FDA XXII SoGAT meeting HIV genetic diversity:

More information

Letter from the CEO. Dear Friends of IAVI,

Letter from the CEO. Dear Friends of IAVI, IAVI Annual Report 2017 Letter from the CEO Dear Friends of IAVI, We are pleased to present an overview of the progress IAVI and partners have made in 2017 toward our pursuit of the development of vaccines

More information

DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED

DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps

More information

The Third D: Long Term Solutions to End the Epidemic. Mitchell Warren Executive Director, AVAC 12 February 2014

The Third D: Long Term Solutions to End the Epidemic. Mitchell Warren Executive Director, AVAC 12 February 2014 The Third D: Long Term Solutions to End the Epidemic Mitchell Warren Executive Director, AVAC 12 February 2014 Key clinical trial milestones: HIV vaccine research First HIV vaccine trial opens Phase

More information

RAISON D ETRE OF THE IMMUNE SYSTEM:

RAISON D ETRE OF THE IMMUNE SYSTEM: RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Acquired Immunity Innate immunity: (Antigen nonspecific) defense

More information

Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses

Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses Weimin Liu University of Alabama at Birmingham Introduction and Rationale Virus-like particles (VLPs)

More information

Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of Our forward looking

Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of Our forward looking EBOLA HIV January 2015 Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of 1995. Our forward looking statements represent our current

More information

Activation of NK Cells by ADCC Antibodies and HIV Disease Progression

Activation of NK Cells by ADCC Antibodies and HIV Disease Progression RAPID COMMUNICATION Activation of NK Cells by ADCC Antibodies and HIV Disease Progression Amy W. Chung, BSc, PhD,* Marjon Navis, PhD,* Gamze Isitman, BSc,* Leia Wren, BSc,* Julie Silvers, RN, Janaki Amin,

More information